Background and Purpose
Ischemic stroke is a heterogeneous disease with various etiologies. The current subtyping process is complicated, time-consuming, and costly. Metabolite-based biomarkers have the potential to improve classification and deliver optimal treatments. We here aimed to identify novel, targeted metabolomics-based biomarkers to discriminate between large-artery atherosclerosis (LAA) and cardioembolic (CE) stroke.
We acquired serum samples and clinical data from a hospital-based acute stroke registry (ischemic stroke within 3 days from symptom onset). We included 346 participants (169 LAA, 147 CE, and 30 healthy older adults) and divided them into training and test sets. Targeted metabolomic analysis was performed using quantitative and quality-controlled liquid chromatography with tandem mass spectrometry. A multivariate regression model using metabolomic signatures was created that could independently distinguish between LAA and CE strokes.
The training set (n = 193) identified metabolomic signatures that were different in patients with LAA and CE strokes. Six metabolomic biomarkers, i.e., lysine, serine, threonine, kynurenine, putrescine, and lysophosphatidylcholine acyl C16:0, could discriminate between LAA and CE stroke after adjusting for sex, age, body mass index, stroke severity, and comorbidities. The enhanced diagnostic power of key metabolite combinations for discriminating between LAA and CE stroke was validated using the test set (n = 123).
We observed significant differences in metabolite profiles in LAA and CE strokes. Targeted metabolomics may provide enhanced diagnostic yield for stroke subtypes. The pathophysiological pathways of the identified metabolites should be explored in future studies.
This is a preview of subscription content,to check access.
Access this article
Similar content being viewed by others
The data that support the findings of this study are available from the corresponding author upon reasonable request.
The Trial of ORG 10172 in Acute Stroke Treatment
Recombinant tissue plasminogen activator
Liquid chromatography with tandem mass spectrometry
False discovery rate
Area under the receiver operating curve
Indoleamine 2, 3-dioxygenase 1
Adjusted odds ratio
Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20:795–820.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic stroke: research and practice. Circ Res. 2017;120:527–40.
Amarenco P, Bogousslavsky J, Caplan L, Donnan G, Hennerici M. Classif stroke Subtypes. Cerebrovasc Dis. 2009;27:493–501.
Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52:e364–467.
Audebert HJ, Saver JL, Starkman S, Lees KR, Endres M. Prehospital stroke care: new prospects for treatment and clinical research. Neurol. 2013;81:501–8.
Sharobeam A, Jones B, Walton-Sonda D, Lueck CJ. Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature. J Neurol. 2021;268:2723–34.
Yamamoto H, Bogousslavsky J, van Melle G. Different predictors of neurological worsening in different causes of stroke. Arch Neurol. 1998;55:481–6.
Regenhardt RW, Das AS, Lo EH, Caplan LR. Advances in understanding the pathophysiology of lacunar stroke: a review. JAMA Neurol. 2018;75:1273–81.
Johnson C, Kittner S, McCarter R, Sloan M, Stern B, Buchholz D, et al. Interrater reliability of an etiologic classification of ischemic stroke. Stroke. 1995;26:46–51.
Radu RA, Terecoasă EO, Băjenaru OA, Tiu C. Etiologic classification of ischemic stroke: where do we stand? Clin Neurol neurosurg. 2017;159:93–106.
Stahrenberg R, Weber-Krüger M, Seegers J, Edelmann F, Lahno R, Haase B, et al. Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke. 2010;41:2884–8.
Flach C, Muruet W, Wolfe CD, Bhalla A, Douiri A. Risk and secondary prevention of stroke recurrence: a population-base cohort study. Stroke. 2020;51:2435–44.
Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17:451–9.
Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99:1819–75.
Yang Q, Zhang A-h, Miao J-h, Sun H, Han Y, Yan G-l, et al. Metabolomics biotechnology, applications, and future trends: a systematic review. RSC Adv. 2019;9:37245–57.
Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol. 2012;98(30):2.1–2.24.
Simpkins AN, Janowski M, Oz HS, Roberts J, Bix G, Doré S, et al. Biomarker application for precision medicine in stroke. Transl Stroke Res. 2020;11:615–27.
Balasubramanian R, Hu J, Guasch-Ferre M, Li J, Sorond F, Zhao Y, et al. Metabolomic profiles associated with incident ischemic stroke. Neurol. 2022;98:e483–e92.
Sidorov E, Sanghera DK, Vanamala JK. Biomarker for ischemic stroke using metabolome: a clinician perspective. J Stroke. 2019;21:31.
Kim DJ, Cho EJ, Yu K-S, Jang I-J, Yoon J-H, Park T, et al. Comprehensive metabolomic search for biomarkers to differentiate early stage hepatocellular carcinoma from cirrhosis. Cancers. 2019;11:1497.
Kim DJ, Oh JY, Rhee CK, Park SJ, Shim JJ, Cho J-Y. Metabolic fingerprinting uncovers the distinction between the phenotypes of tuberculosis associated COPD and smoking-induced COPD. Front in Med. 2021;8:619077.
Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke. 1999;30:2513–6.
Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32:2559–66.
Lodder J, Bamford JM, Sandercock PA, Jones LN, Warlow CP. Are hypertension or cardiac embolism likely causes of lacunar infarction? Stroke. 1990;21:375–81.
Mitta N, Sreedharan SE, Sarma SP, Sylaja PN. Women and stroke: different, yet similar. Cerebrovasc Dis Extra. 2021;11:106–11.
Kondoh T, Kameishi M, Mallick HN, Ono T, Torii K. Lysine and arginine reduce the effects of cerebral ischemic insults and inhibit glutamate-induced neuronal activity in rats. Front Integr neurosci. 2010;4:18.
Cheng J, Tang J-C, Pan M-X, Chen S-F, Zhao D, Zhang Y, et al. l-lysine confers neuroprotection by suppressing inflammatory response via microRNA-575/PTEN signaling after mouse intracerebral hemorrhage injury. Exp Neurol. 2020;327:113214.
Arboix A, Alioc J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2010;6:150–61.
Lee Y, Khan A, Hong S, Jee SH, Park YH. A metabolomic study on high-risk stroke patients determines low levels of serum lysine metabolites: a retrospective cohort study. Mol BioSyst. 2017;13:1109–20.
Ferro JM. Atrial fibrillation and cardioembolic stroke. Minerva Cardioangiol. 2004;52:111–24.
Heijman J, Ghezelbash S, Wehrens XH, Dobrev D. Serine/threonine phosphatases in atrial fibrillation. J Mol Cell Cardiol. 2017;103:110–20.
Heijman J, Dewenter M, El-Armouche A, Dobrev D. Function and regulation of serine/threonine phosphatases in the healthy and diseased heart. J Mol Cell Cardiol. 2013;64:90–8.
Song P, Ramprasath T, Wang H, Zou M-H. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. Cell Mol Life Sci. 2017;74:2899–916.
Gáspár R, Halmi D, Demján V, Berkecz R, Pipicz M, Csont T. Kynurenine Pathway metabolites as potential clinical biomarkers in coronary artery disease. Front in immunol. 2021:12.
Wongpraparut N, Pengchata P, Piyophirapong S, Panchavinnin P, Pongakasira R, Arechep N, et al. Indoleamine 2, 3 dioxygenase (IDO) level as a marker for significant coronary artery disease. BMC Cardiovasc Disord. 2021;21:1–10.
Wang Y, Liu H, McKenzie G, Witting PK, Stasch J-P, Hahn M, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16:279–85.
Yurdagul A Jr, Kong N, Gerlach BD, Wang X, Ampomah P, Kuriakose G, et al. ODC (ornithine decarboxylase)-dependent putrescine synthesis maintains MerTK (MER tyrosine-protein kinase) expression to drive resolution. Arteriosclerosis, Thromb, Vasc Biol. 2021;41:e144–e59.
Yurdagul A Jr, Subramanian M, Wang X, Crown SB, Ilkayeva OR, Darville L, et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 2020;31(518-33):e10.
Soehnlein O, Libby P. Targeting inflammation in atherosclerosis—from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20:589–610.
Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem. 2007;14:3209–20.
Schmitz G, Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis. 2010;208:10–8.
Mannheim D, Herrmann J, Versari D, Gössl M, Meyer FB, McConnell JP, et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke. 2008;39:1448–55.
Haid M, Muschet C, Wahl S, Römisch-Margl W, Prehn C, Möller G, et al. Long-term stability of human plasma metabolites during storage at -80 °C. J Proteome Res. 2018;17:203–11.
Hustad S, Eussen S, Midttun Ø, Ulvik A, van de Kant PM, Mørkrid L, et al. Kinetic modeling of storage effects on biomarkers related to B vitamin status and one-carbon metabolism. Clin Chem. 2012;58:402–10.
Wagner-Golbs A, Neuber S, Kamlage B, Christiansen N, Bethan B, Rennefahrt U, et al. Effects of long-term storage at -80 °C on the human plasma metabolome. Metabolites. 2019:9.
Yang W, Chen Y, Xi C, Zhang R, Song Y, Zhan Q, et al. Liquid chromatography-tandem mass spectrometry-based plasma metabonomics delineate the effect of metabolites’ stability on reliability of potential biomarkers. Anal Chem. 2013;85:2606–10.
The bio-specimens and data used for this study were provided by the Biobanks of Seoul National University Hospital and Ajou University Hospital, members of the Korea Biobank Network.
This work was supported by grants from the National Research Foundation of Korea (NRF), funded by the Korean government (MSIT) (2020R1A2C1100337). The funding agencies had no role in the design of the study.
This study was approved by the local institutional review board (Seoul National University Hospital IRB No. 2006-077-1131) and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent for blood and clinical data collection was obtained from all the participants.
Conflict of Interest
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lee, EJ., Kim, D.J., Kang, DW. et al. Targeted Metabolomic Biomarkers for Stroke Subtyping. Transl. Stroke Res. (2023). https://doi.org/10.1007/s12975-023-01137-5